Javascript must be enabled to continue!
TU‐H‐CAMPUS‐JeP3‐04: Factors Predicting a Need for Treatment Replanning with Proton Radiotherapy for Lung Cancer
View through CrossRef
Purpose:Proton dose distribution is sensitive to tumor regression and tissue and normal anatomy changes. Replanning is sometimes necessary during treatment to ensure continue tumor coverage or avoid overtreatment of organs at risk (OARs). We investigated action thresholds for replanning and identified both dosimetric and non‐dosimetric metrics that would predict a need for replan.Methods:All consecutive lung cancer patients (n = 188) who received definitive proton radiotherapy and had more than two evaluation CT scans at the Roberts Proton Therapy Center (Philadelphia, USA) from 2011 to 2015 were included in this study. The cohort included a variety of tumor sizes, locations, histology, beam angles, as well as radiation‐induced tumor and lung change. Dosimetric changes during therapy were characterized by changes in the dose volume distribution of PTV, ITV, and OARs (heart, cord, esophagus, brachial plexus and lungs). Tumor and lung change were characterized by changes in sizes, and in the distribution of Hounsfield numbers and water equivalent thickness (WET) along the beam path. We applied machine learning tools to identify both dosimetric and non‐dosimetric metrics that predicted a replan.Results:Preliminary data showed that clinical indicators (n = 54) were highly correlated; thus, a simple indicator may be derived to guide the action threshold for replanning. Additionally, tumor regression alone could not predict dosimetric changes in OARs; it required further information about beam angles and tumor locations.Conclusion:Both dosimetric and non‐dosimetric factors are predictive of the need for replanning during proton treatment.
Title: TU‐H‐CAMPUS‐JeP3‐04: Factors Predicting a Need for Treatment Replanning with Proton Radiotherapy for Lung Cancer
Description:
Purpose:Proton dose distribution is sensitive to tumor regression and tissue and normal anatomy changes.
Replanning is sometimes necessary during treatment to ensure continue tumor coverage or avoid overtreatment of organs at risk (OARs).
We investigated action thresholds for replanning and identified both dosimetric and non‐dosimetric metrics that would predict a need for replan.
Methods:All consecutive lung cancer patients (n = 188) who received definitive proton radiotherapy and had more than two evaluation CT scans at the Roberts Proton Therapy Center (Philadelphia, USA) from 2011 to 2015 were included in this study.
The cohort included a variety of tumor sizes, locations, histology, beam angles, as well as radiation‐induced tumor and lung change.
Dosimetric changes during therapy were characterized by changes in the dose volume distribution of PTV, ITV, and OARs (heart, cord, esophagus, brachial plexus and lungs).
Tumor and lung change were characterized by changes in sizes, and in the distribution of Hounsfield numbers and water equivalent thickness (WET) along the beam path.
We applied machine learning tools to identify both dosimetric and non‐dosimetric metrics that predicted a replan.
Results:Preliminary data showed that clinical indicators (n = 54) were highly correlated; thus, a simple indicator may be derived to guide the action threshold for replanning.
Additionally, tumor regression alone could not predict dosimetric changes in OARs; it required further information about beam angles and tumor locations.
Conclusion:Both dosimetric and non‐dosimetric factors are predictive of the need for replanning during proton treatment.
Related Results
Anais da VIII Jornada Odontológica da Unicastelo
Anais da VIII Jornada Odontológica da Unicastelo
CATEGORIA PAINELP 01. NÓDULOS PULPARES - CALCIFICAÇÕES. TAVARES, THAÍS RUAS; SEKI, NATHALIA MARIKO ASSAKAWA; SOUZA, EDMARA REGINA DIAS; SIVA, AMANDA SOUZA; SIMONATO, LUCIANA ESTEVA...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
MO‐SAM‐BRB‐02: Proton Physics and Technology
MO‐SAM‐BRB‐02: Proton Physics and Technology
The dose localization advantages of proton beams derive primarily from the Bragg peak in the proton stopping distribution. Therefore, the potential clinical gains expected form pro...
Abstract 3329: Lung cancer screening initiative and identification of novel blood biomarkers for early detection of lung cancer
Abstract 3329: Lung cancer screening initiative and identification of novel blood biomarkers for early detection of lung cancer
Abstract
In lung cancer, 81% of patients detected are late-stage, since early-stage patients are generally asymptomatic. Winnebago County has a 14% higher mortali...
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...
Abstract SY38-02: Clinical investigations of obesity in cancer: BMI and other confounders
Abstract SY38-02: Clinical investigations of obesity in cancer: BMI and other confounders
Abstract
Obesity has been linked with increased incidence and worse outcomes of at least 13 human cancers. For other cancers, our understanding of their relationship...

